Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in g...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sampson, John H., Heimberger, Amy B., Archer, Gary E., Aldape, Kenneth D., Friedman, Allan H., Friedman, Henry S., Gilbert, Mark R., Herndon, James E., McLendon, Roger E., Mitchell, Duane A., Reardon, David A., Sawaya, Raymond, Schmittling, Robert J., Shi, Weiming, Vredenburgh, James J., Bigner, Darell D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2010
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020702/
https://ncbi.nlm.nih.gov/pubmed/20921459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.6963
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares